1. Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs
- Author
-
Michael D. Pham, Keith L. Black, Nuriel Moghavem, John S. Yu, Daniel Nwachokor, Rina Amatya, Chi Woo Yoon, Bong Seop Lee, Joe L. Pantoja, Rebekah Na, and Arsen Osipov
- Subjects
Drug ,Article Subject ,media_common.quotation_subject ,lcsh:RS1-441 ,Prodrug ,Pharmacology ,Combinatorial chemistry ,Esterase ,Hydrophobic effect ,lcsh:Pharmacy and materia medica ,chemistry.chemical_compound ,Monomer ,Flufenamic acid ,chemistry ,Drug delivery ,medicine ,IC50 ,media_common ,medicine.drug ,Research Article - Abstract
We demonstrated that hydrophobic derivatives of the nonsteroidal anti-inflammatory drug (NSAID)flufenamic acid (FA), can be formed into stable nanometer-sized prodrugs (nanoprodrugs) that inhibit the growth of glioma cells, suggesting their potential application as anticancer agent. We synthesized highly hydrophobic monomeric and dimeric prodrugs of FA via esterification and prepared nanoprodrugs using spontaneous emulsification mechanism. The nanoprodrugs were in the size range of 120 to 140 nm and physicochemically stable upon long-term storage as aqueous suspension, which is attributed to the strong hydrophobic interaction between prodrug molecules. Importantly, despite the highly hydrophobic nature and water insolubility, nanoprodrugs could be readily activated into the parent drug by porcine liver esterase, presenting a potential new strategy for novel NSAID prodrug design. The nanoprodrug inhibited the growth of U87-MG glioma cells with IC50 of 20 μM, whereas FA showed IC50 of 100 μM, suggesting that more efficient drug delivery was achieved with nanoprodrugs.
- Published
- 2010